



## IMALUX ADDS TO EXECUTIVE STAFF

### For Release: Immediate

**Cleveland, Ohio, June 30, 2005** – Imalux Corporation today announced the addition of two key executives to its management team, a medical director and a director of marketing and sales.

Nancy J. Tresser, M.D., M.B.A., has joined Imalux in the role of Medical Director. Dr. Tresser comes to Imalux with more than 15 years of medical experience in various settings including academics, government, and private practice. Her impressive background includes experience at the National Institutes of Health, National Institute of Neurological Disorders and Stroke, Office of the Clinical Director, in Bethesda, Maryland, where she served as Special Expert, neuropathologist. Dr. Tresser also held the title of Assistant Professor of Pathology at the University of South Florida and University Hospitals of Cleveland/Case Western Reserve University School of Medicine. Additional past experience includes serving as staff neuropathologist at the James A. Haley VA Medical Center and the H. Lee Moffitt Cancer Center, both located in Tampa, Florida.

Dr. Tresser received her M.D. from the University of Michigan Medical School and her M.B.A. from Case Western Reserve University. She has contributed to over 50 publications and presentations, and has lectured at various events in the medical community. Dr. Tresser will lead Imalux's clinical development effort and is the primary interface with the Company's Clinical Advisory Boards.

Jon J. Snyder has also joined Imalux as the Director of Marketing and Sales and for the past several months has directed that effort. He comes to Imalux from Cyberonics, Inc. where he successfully directed the adoption and establishment of the VNS epilepsy therapy program at leading comprehensive epilepsy centers nationwide. Prior to joining Cyberonics, he spent eight years at STERIS Corporation, where he held various roles of increasing responsibility in their marketing department.

Mr. Snyder, who holds a bachelor's degree from Ohio University, will play a vital role in the successful market introduction of the Imalux Niris™ Imaging System. His overall responsibility is the Imalux commercialization effort including management of the Imalux Niris Imaging System product line as well as the execution of the Company's reimbursement strategic plan.

"We are excited to have both Nancy and Jon in their respective roles", stated J. Lloyd Breedlove, President & CEO, "to find talent of their caliber and with an experience base that matches our strategic direction so well is a tremendous asset to Imalux. Jon and I worked together for many years and the opportunity to work with him again is especially gratifying. With little or no learning curve time, Jon has quickly become a vital member of our management team. Nancy's background is custom-made for Imalux and she has made an immediate impact on our clinical initiatives. I am confident that both will play significant roles in the growth of Imalux."

## **About Imalux & the Niris Imaging System**

Imalux is a Cleveland-based corporation that is commercializing Optical Coherence Tomography ("OCT") technology originally developed at the Institute of Applied Physics of the Russian Academy of Sciences, one of the main progenitors of OCT technology worldwide. OCT is a proven technology that is on the verge of becoming the sixth major imaging modality.

The Company's Niris Imaging System provides real-time, high spatial resolution, two-dimensional, cross-sectional depth visualization of tissue microstructure. The compact, point-of-care System creates images utilizing harmless, near infrared light that allow clinicians to visualize normal and abnormal tissue microstructures. The spatial resolution of the System is on the order of 0.01 mm, surpassing conventional ultrasound imaging by an order of magnitude. Imalux OCT technology has been under evaluation with physicians in a number of specialty areas and has been evaluated with more than 3,000 patients worldwide at leading medical institutions including The Cleveland Clinic Foundation, The George Washington University Medical Center, and University Hospitals of Cleveland.

The Niris Imaging System has received market clearance from the U.S. Food & Drug Administration, and Imalux recently demonstrated Niris at the American Urological Association annual meeting in San Antonio, Texas and Digestive Disease Week 2005 in Chicago, Illinois.

### **Contact information:**

Imalux Corporation  
J. Lloyd Breedlove  
President & CEO  
Phone: 216-502-0755  
[jlbreedlove@imalux.com](mailto:jlbreedlove@imalux.com)  
web: [www.imalux.com](http://www.imalux.com)